

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached SCHEDULE A under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number: **46037**

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: **46037**

OR

☒ Firm or Individual Name **Peter F. Corless  
EDWARDS ANGELL PALMER & DODGE LLP**

Address **P.O. Box 55874**

City **Boston**

State

**MA**

Zip

**02205**

Country **US**

Telephone

**(617) 239-0100**

Email

**pcorless@eapdlaw.com**


Assignee Name and Address:

Government of the United States of America,  
as represented by the Secretary, Department of Health and Human Services  
6011 Executive Boulevard  
Suite 325  
Rockville, Maryland 20852

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/98 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

### SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	<b>September 9, 2009</b>
Name	<b>Jasbir Kindra</b>	Telephone	<b>(301) 435-5170</b>
Title	<b>Chief, General Medicine Branch</b>		

SCHEDULE A					Short Title
Docket No.	Filed	Issued	Patent No.	Inventor	
84254CIP(47992)	10/31/2005			Nabel, E.	PROTEIN ARGININE N-METHYLTRANSFERASE 2
84255(47992)	8/24/2006			Trepel, J.	PHARMACODYNAMIC ASSAYS
84310(47992)	2/12/2008			Pierre, D.	NEURONAL AVALANCHE ASSAY
84321(47992)	9/17/2008			Markoff, L.	WEST NILE VIRUSES WITH MUTATIONS IN THE 3' TERMINA
84330(47992)	7/9/2004			Brown, K.	INFECTIOUS CLONE OF HUMAN PARVOVIRUS B19 AND METHO
84403(47992)	6/7/2006			Lal, C.	MONOCLONAL ANTIBODIES THAT BIND OR NEUTRALIZE DENG
84404CON3(47992)	5/27/1994	2/6/2001	6,184,024	Lal, C.	CHIMERIC AND/OR GROWTH-RESTRICTED FLAVIVIRUSES
84404CON4(47992)	8/19/2000	1/13/2004	6,676,936	Lal, C.	CHIMERIC AND/OR GROWTH-RESTRICTED FLAVIVIRUSES
84405(47992)	11/21/2003	6/5/2007	7,236,602	Whitehead, S.	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DE
84405CON(47992)	3/2/2009			Whitehead, S.	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING D
84405DIV(47992)	6/3/2006	7/14/2009	7,560,118	Whitehead, S.	DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING D
84406(47992)	7/26/2002	9/21/2004	6,794,174	Platnev, A.	FULL-LENGTH INFECTIOUS CDNA CLONES OF TICK BORNE F
84408DIV(47992)	10/27/2005			Gu, X.	INTRANASAL IMMUNIZATION
84412(47992)	9/5/2003	4/28/2009	7,624,508	Pang, X.	SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
84412CON(47992)	2/27/2009			Pang, X.	SUBGENOMIC REPLICONS OF THE FLAVIVIRUS DENGUE
84475(47992)	7/18/2001	6/6/2006	7,056,734	Egan, J.	DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS
84475CON(47792)	4/7/2006			Egan, J.	DIFFERENTIATION OF NON-INSULIN PRODUCING CELLS
84481(47992)	10/21/2004	4/74/2009	7,517,531	Whitehead, S.	DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30
84491CON(47992)	3/4/2008			Whitehead, S.	DENGUE TETRAVALENT VACCINE CONTAINING A COMMON 30
84493(47992)	3/2/2001	2/3/2004	6,885,943	Zeng, L.	REPLICATION-DEFECTIVE DENGUE VIRUSES THAT ARE REPL
84550(47992)	1/3/2006			Cohen, J.	SAFER ATTENUATED VIRUS VACCINES WITH MISSING OR DI

84551(47992)	11/21/2008			Wong, S.	ERYTHROID PROGENITOR CELLS METHODS RELATED TO THE TREATMENT OF NEURODEGENERAT
84553(47992)	8/10/2007			Hong, J.	COMPOSITION FOR DETECTING THE RESPONSE OF RECTAL A
84554(47992)	7/12/2008			Reid, T.	GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF
84520(47992)	4/1/2006	8/18/2009	7,576,050	Greig, N.	GLP-1 EXENDIN-4 PEPTIDE ANALOGS AND USES THEREOF
845200CN(47992)	12/18/2008			Greig, N.	